In our season six finale, we dive deeper into how artificial intelligence (AI) is shaping the future of drug discovery and scientific research. With remarkable scale and speed, AI models parse through complex datasets and confirm or generate hypotheses, which can help scientists accelerate R&D. In this episode, co-host Danielle Mandikian welcomes Aviv Regev, Head of gRED, and Jure Leskovec, Professor of Computer Science at Stanford University, to talk about foundation models and autonomous agents. Together, they explore the opportunities and challenges of applying AI in drug discovery, including balancing innovation with scientific rigor and the evolving role of scientists. They also discuss how AI is reshaping the future of research — from building more biologically meaningful models to advancing agent-based systems and lab automation.
Read the full text transcript at www.gene.com/stories/foundation-models-and-agents
All content for Two Scientists Walk Into a Bar is the property of Genentech and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
In our season six finale, we dive deeper into how artificial intelligence (AI) is shaping the future of drug discovery and scientific research. With remarkable scale and speed, AI models parse through complex datasets and confirm or generate hypotheses, which can help scientists accelerate R&D. In this episode, co-host Danielle Mandikian welcomes Aviv Regev, Head of gRED, and Jure Leskovec, Professor of Computer Science at Stanford University, to talk about foundation models and autonomous agents. Together, they explore the opportunities and challenges of applying AI in drug discovery, including balancing innovation with scientific rigor and the evolving role of scientists. They also discuss how AI is reshaping the future of research — from building more biologically meaningful models to advancing agent-based systems and lab automation.
Read the full text transcript at www.gene.com/stories/foundation-models-and-agents
As we kick off season six, we’re diving deeper into one of our most popular topics from last season – our evolving understanding of obesity. In this episode, co-host Maria Wilson unpacks the latest in obesity biology and management with Manu Chakravarthy, Senior Vice President and Global Head of Cardiovascular, Renal and Metabolism Product Development, who discusses the stigma associated with obesity and how thousands of years of human evolution contribute to this chronic condition. While lifestyle, diet and exercise modifications are still essential in addressing the biological factors that drive obesity, they explore how emerging treatments have the potential to rewire the brain’s hunger and satiety signals – offering a more personalized, sustainable approach.
Read the full text transcript at www.gene.com/stories/digging-deeper-into-obesity
Two Scientists Walk Into a Bar
In our season six finale, we dive deeper into how artificial intelligence (AI) is shaping the future of drug discovery and scientific research. With remarkable scale and speed, AI models parse through complex datasets and confirm or generate hypotheses, which can help scientists accelerate R&D. In this episode, co-host Danielle Mandikian welcomes Aviv Regev, Head of gRED, and Jure Leskovec, Professor of Computer Science at Stanford University, to talk about foundation models and autonomous agents. Together, they explore the opportunities and challenges of applying AI in drug discovery, including balancing innovation with scientific rigor and the evolving role of scientists. They also discuss how AI is reshaping the future of research — from building more biologically meaningful models to advancing agent-based systems and lab automation.
Read the full text transcript at www.gene.com/stories/foundation-models-and-agents
